Yang Xin, Liu Xiaojing, Wang Li, Xu Juan, Wen Juan
Infection Department, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ann Palliat Med. 2023 Jan;12(1):163-170. doi: 10.21037/apm-22-1422.
Hypoglycemia is a common phenomenon in patients with various severe liver diseases. However, its implications for the prognosis of patients with acute on chronic liver failure remains largely unknown. This study investigated the status of hypoglycemia in patients with acute on chronic liver failure, as well as its risk factors and correlation with 90-day patient outcomes.
A total of 218 patients with acute on chronic liver failure diagnosed and treated in our hospital from January 2019 to August 2021 were enrolled. Hypoglycemia is defined as a fasting blood glucose level ≤2.8 mmol/L. Baseline data on the patients' clinical characteristics and laboratory examinations were collected. Patients were followed-up with a primary outcome of 90-day mortality. The risk factors for hypoglycemia were identified by univariate and multivariate logistic regression.
A total of 99 cases (45.41%) had hypoglycemia. Liver cirrhosis [odds ratio (OR) =5.16, P<0.001] and a higher model for end-stage liver disease (MELD) score (OR =1.29, P<0.001) were risk factors for hypoglycemia in acute on chronic liver failure, while higher fibrinogen (FIB) was a protective factor for hypoglycemia (OR =0.17, P=0.001). The 90-day mortality rate in the hypoglycemia group was significantly higher than that in the non-hypoglycemia group (72.73% vs. 48.74%, P<0.001). After adjusting for hepatic encephalopathy, cirrhosis, and MELD scores, hypoglycemia (OR =8.72, P=0.01) was still an independent risk factor for 90-day mortality in patients with acute on chronic liver failure.
Hypoglycemia is common in patients with acute on chronic liver failure and is related to poor prognosis. Patients with cirrhosis, a higher MELD score, and a significant decrease in FIB are more likely to develop hypoglycemia. Thus whether ameliorating hypoglycemia could improve patient outcomes deserves additional investigations.
低血糖是各种严重肝脏疾病患者中的常见现象。然而,其对慢性肝衰竭急性发作患者预后的影响在很大程度上仍不清楚。本研究调查了慢性肝衰竭急性发作患者的低血糖状况、危险因素及其与患者90天预后的相关性。
纳入2019年1月至2021年8月在我院诊断和治疗的218例慢性肝衰竭急性发作患者。低血糖定义为空腹血糖水平≤2.8 mmol/L。收集患者临床特征和实验室检查的基线数据。对患者进行随访,主要结局为90天死亡率。通过单因素和多因素逻辑回归确定低血糖的危险因素。
共有99例(45.41%)发生低血糖。肝硬化[比值比(OR)=5.16,P<0.001]和较高的终末期肝病模型(MELD)评分(OR =1.29,P<0.001)是慢性肝衰竭急性发作患者低血糖的危险因素,而较高的纤维蛋白原(FIB)是低血糖的保护因素(OR =0.17,P=0.001)。低血糖组的90天死亡率显著高于非低血糖组(72.73%对48.74%,P<0.001)。在调整肝性脑病、肝硬化和MELD评分后,低血糖(OR =8.72,P=0.01)仍然是慢性肝衰竭急性发作患者90天死亡率的独立危险因素。
低血糖在慢性肝衰竭急性发作患者中很常见,且与预后不良有关。肝硬化患者、较高的MELD评分以及FIB显著降低的患者更容易发生低血糖。因此,改善低血糖是否能改善患者预后值得进一步研究。